BioPass Pharma
Targeting Drugs and Molecules into the Brain
Company Overview
Snapshot
Founded in October 2021 by Elka Touitou, Tal Ben Yehuda, Shlomi Zandberg, and Hiba Natsheh, BioPass Pharma operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing a patented novel technology for drug delivery to the brain.
Business overview
BioPass Pharma is a Health Tech & Life Sciences company specializing in drug delivery within the Pharma & Medical Biotechnology sector. The company is developing a revolutionary formulation designed to deliver drugs and molecules directly into the brain, bypassing the blood-brain barrier (BBB). Its core technology involves a novel nasal formulation that offers a non-invasive, painless, and easily administered treatment with a short onset, avoiding gastrointestinal and hepatic presystemic metabolism. BioPass Pharma serves the healthcare and life sciences markets, particularly targeting patients with CNS diseases, and operates within the drug delivery and nanotechnology categories.
Log in to access full profile ›Company Intelligence Q&A
- What is BioPass Pharma's primary focus?
- BioPass Pharma is focused on developing a revolutionary formulation for the treatment of brain or CNS diseases. The company's patented novel technology is designed to deliver molecules directly into the brain by bypassing the blood-brain barrier.
- What is the core technology behind BioPass Pharma's approach?
- The core technology is a novel nasal formulation that enables non-invasive, painless, and easily administered drug delivery. This method offers a short onset of action and avoids gastrointestinal and hepatic presystemic metabolism.
- When was BioPass Pharma founded?
- BioPass Pharma was founded in October 2021.
- Who are the founders of BioPass Pharma?
- BioPass Pharma was founded by Elka Touitou, Tal Ben Yehuda, Shlomi Zandberg, and Hiba Natsheh.
- What is the current product development stage for BioPass Pharma?
- BioPass Pharma's products, including Targeted Carrier Formulation, nasal drug delivery carrier, and Phospholipid Magnesome, are currently in the R&D stage.